Fig 1.
The structure of the partitioned survival model.
PFS, progression-free survival; PD, progressed disease.
Table 1.
Survival model parameters fitting to the PFS and OS data from the OptiTROP-Breast01 trial.
Table 2.
Model inputs: baseline value, ranges, and distribution.
Table 3.
The results of base-case analyses.
Fig 2.
Tornado diagram of one-way sensitivity analyses of sacituzumab tirumotecan versus chemotherapy.
PFS, progression-free survival; PD, progressed disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Fig 3.
Cost-effectiveness acceptability curves of sacituzumab tirumotecan versus chemotherapy.
WTP, willingness-to-pay; QALY, quality-adjusted life-year.